NICE endorses Tepmetko^® as first and only targeted oral treatment for METex14 mutated NSCLC

The National Institute for Health and Care Excellence (NICE) has endorsed Tepmetko® (tepotinib) for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with METex14 skipping alterations. In the VISION study, tepotinib demonstrated significant benefits including slowing disease progression and extending survival. NSCLC makes up 87% of lung cancer cases with 3–4% of advanced NSCLC cases displaying METex14 skipping alterations. NSCLCs with MET alterations have a poorer prognosis and lower median survival than cases without alterations. Exon 14 on the MET gene plays an essential role in the breakdown of the MET protein. METex14 skipping alterations result in...